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An association between the metabolic syndrome and reduced testosterone levels has been identified, and a specific inverse
relationship between insulin and testosterone levels suggests that an important metabolic crosstalk exists between these two
hormonal axes; however, the mechanisms by which insulin and androgens may be reciprocally regulated are not well described.
Androgen-dependant gene pathways regulate the growth and maintenance of both normal and malignant prostate tissue, and
androgen-deprivation therapy (ADT) in patients exploits this dependence when used to treat recurrent and metastatic prostate
cancer resulting in tumour regression. A major systemic side effect of ADT includes induction of key features of the metabolic
syndrome and the consistent feature of hyperinsulinaemia. Recent studies have specifically identified a correlation between elevated
insulin and high-grade PCa and more rapid progression to castrate resistant disease. This paper examines the relationship between
insulin and androgens in the context of prostate cancer progression. Prostate cancer patients present a promising cohort for
the exploration of insulin stabilising agents as adjunct treatments for hormone deprivation or enhancers of chemosensitivity for
treatment of advanced prostate cancer.
1. Prostate Cancer and the Metabolic Syndrome
The metabolic syndrome describes a cluster of comorbidities
including abdominal obesity, elevated blood glucose, high
cholesterol, and hypertension, which increase the risk of
developing diabetes and cardiovascular disease [1]. Many of
these factors have also been established as risk factors for
prostate cancer, strongly suggesting that there is a metabolic
component to this malignancy [2–6].
Epidemiological studies have also shown that patients
with existing obesity are more likely to be diagnosed with
higher-grade cancers and higher Gleason scores, have a high-
er rate of positive surgical margins at radical prostatectomy,
and suffer a higher incidence of prostate cancer recurrence
and higher risk of dying of prostate cancer than men with a
healthy body mass index (BMI) [7–9]. A number of factors
are thought to contribute to these findings including not only
a biologic effect by which the endocrine abnormalities of the
metabolic syndrome favour aggressive behaviour of prostate
cancer but also difficulty in detection as the high rate of
benign prostatic hyperplasia (BPH) in obese men increases
the likelihood of missing abnormalities with prostate biop-
sies [10] and misdiagnosis following screening using the
prostate-specific antigen (PSA) biomarker; obese men have
been reported to have both lower measured PSA, due to in-
creased blood volume and increased PSA concomitant with
increased prostate volume and BPH [3], making prostate ir-
regularities complicated to assess.
Dyslipidaemia associated with the metabolic syndrome,
including increased triglycerides and LDL and decreased
HDL, is also associated with increased prostate cancer risk
[11–13], and cholesterol-lowering medications such as sta-
tins are currently believed to exert most of their positive
effects via systemic reductions in total cholesterol [14]. Both
dietary and de novo synthesis of free fatty acids have been
shown to promote prostate cancer cell survival [15, 16],
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but studies which characterise fatty acid profiles in prostate
disease remain controversial [17, 18].
The metabolic syndrome is associated with altered hor-
monal profiles for testosterone, insulin, IGFs, and oestrogen,
all of which are linked to prostate cancer [19–22]. An asso-
ciation between the metabolic syndrome and reduced testos-
terone levels exists [9, 23–26] which is not simply related to
age [27, 28]. The specific inverse relationship between insulin
and testosterone levels observed across the age range from
pubertal boys and young men to the elderly (19–90+ years)
[26, 28, 29] suggests that an important metabolic crosstalk
exists between these two hormonal axes.
2. Androgen-Deprivation Therapy and
Castrate-Resistant Prostate Cancer
Prostate cancer (PCa) is the most commonly diagnosed le-
thal cancer in men accounting for approximately one-third
of all cancers with a relative lifetime risk of 1 in 7. Its
incidence continues to rise with an ageing population, and
despite improved survival rates, it remains the second leading
cause of cancer deaths in western men [30, 31]. In general,
patients with organ-confined PCa are initially treated with
radical prostatectomy or radiation-based therapies; however,
25–40% of patients will experience biochemical recurrence
defined by a rise in prostate-specific antigen (PSA), an an-
drogen-regulated gene which in these patients acts as a bio-
marker of recurrent prostate tumour growth and metastatic
progression [32]. For decades the most common treatment
for metastatic PCa has been androgen-deprivation thera-
py (ADT) which suppresses testicular testosterone produc-
tion. Androgen supply is controlled centrally via the hypo-
thalamic-pituitary-testicular axis. Luteinizing hormone-re-
leasing hormone (LHRH) is released from the hypothalamus
to activate the anterior pituitary to produce Luteinizing hor-
mone (LH), which stimulates testosterone production from
the Leydig cells of the testes. LHRH production is eventual-
ly inhibited by the ligand-mediated activation of the an-
drogen receptor [33]. Androgen deprivation is generally
achieved using the class of LHRH agonists such as goserelin
acetate which disrupts pituitary stimulation and causes dra-
matic decreases in LH production and subsequent castrate
testosterone levels.
Most patients initially respond to ADT; however, after
a median 18–36 months patients recur with rising PSA
levels despite castrate androgen levels in the serum. This is
termed castrate-resistant prostate cancer (CRPC) and leads
to significant comorbidities and inevitable mortality [32, 34–
36]. The recurrent expression of PSA following the nadir
with androgen deprivation therapy implies resumption of
androgen receptor activation during progression to castrate
resistance. Similarly the fact that up to 30% of patients
respond to secondary androgen axis manipulation during
castrate resistance implies an ongoing dependence on the
androgen receptor pathway in these patients [37]. At least
three mechanisms contribute to the reactivation of the
androgen receptor in prostate cancer progression. Mutations
or splicing events to the ligand binding domain of the
androgen receptor (AR) give rise to a promiscuous receptor
which permits activation by other molecules including other
steroid hormones and antiandrogens (e.g., flutamide) [38].
Amplification of the AR gene has been reported in 30% of
tumour samples and is often accompanied by an increase
in AR stabilization [35]. A third mechanism followed the
observation that, despite low circulating androgen levels with
ADT, intraprostatic levels of testosterone in CRPC are high
[39]. We and others subsequently demonstrated that, in the
face of ADT, prostate tumours upregulate expression of the
enzymes necessary to synthesise their own androgens de
novo [37, 40, 41] resulting in paracrine and autocrine supply
of androgens in the prostate tumour microenvironment
to sufficient levels to reactivate AR-driven pathways and
promote CRPC [40].
Current standard cytotoxic chemotherapies have shown
limited benefit for the treatment of CRPC, with modest
survival benefits of 2–5 months with docetaxel (Taxotere or
cabazitaxel) [42]. The discovery of de novo steroidogenesis in
prostate tumours as a mechanism driving CRPC has played a
significant part in rationalising the newly approved steroido-
genic CYP17A1 inhibitor, abiraterone, which is showing
great clinical promise for improved control of CRPC [43, 44].
However ∼50% of men treated are or ultimately become
resistant to abiraterone highlighting the urgent need to un-
derstand the factors driving this resistance to develop alter-
native or adjuvant treatment options [45].
What is striking in patients undergoing ADT is the rapid
onset of several key features of the metabolic syndrome in
men with no preexisting metabolic dysfunction.
3. Androgen Deprivation Causes
Metabolic Dysfunction
While ADT is initially an effective treatment for prostate
cancer for most patients, the systemic side effects include
key features of the metabolic syndrome. Patients typically
experience a loss of muscle mass, increased fat mass, and the
development of central adiposity, hyperlipidaemia, increased
risk of cardiovascular mortality, hyperglycaemia, and the
consistent feature of hyperinsulinaemia [46–48]. These in
turn are associated with poor outcomes includingmore rapid
progression to advanced disease and increased cancer mor-
tality [6, 49, 50]. Moreover, recent studies have specifically
identified a correlation between elevated insulin/C-peptide
levels (normalized surrogate insulin levels) with high-grade
PCa and worse patient prognosis [6, 9, 47, 51–54]. Pre-
diagnostic body mass index (BMI) and C-peptide correlate
with the risk of prostate cancer-specific mortality, and obese
men (BMI> 30) were more likely to have extraprostatic or
metastatic prostate cancer, or a higher Gleason grade of
cancer at the time of diagnosis than men with BMI < 30.
Of greater significance, patients with higher C-peptide had
an increased prostate cancer-specific mortality compared to
those with low C-peptide levels suggesting that at least part of
the effect of increased BMI on mortality was related to coin-
cident hyperinsulinaemia [6]. Similarly, a nested case-control
trial within the Prostate Cancer Prevention Trial found
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that while increasing C-peptide level was weakly associated
with cancer risk, there was a strong association with the
development of high-grade prostate cancer of Gleason grade
7 or greater. In contrast to the Ma study, this association
was found to be independent of BMI [54]. J. Hammarsten
and B.Ho¨gstedt prospectively assessed baseline insulin levels
at time of prostate cancer diagnosis and compared them
between men who died from prostate cancer during 5 years
of followup and men who survived. Statistically significant
risk factors identified for lethal prostate cancer included both
type 2 diabetes and hyperinsulinaemia. But only hyperin-
sulinaemia remained significant after adjusting for stage and
grade of prostate cancer, factors known to independently
affect prognosis, strongly suggesting that hyperinsulinaemia
is the key promoter of prostate cancer progression associated
with metabolic dysfunction [53]. Thus, while ADT initially
is effective treatment for prostate cancer, the metabolic
complications of ADT may not only cause multisystem
morbidity (obesity, increased risk of stroke, and so forth) but
also lead to an altered hormonal environment that favours
the development of castrate-resistant behaviour.
4. Chicken or the Egg: The Interrelationship
between Insulin and Testosterone
While we have just discussed the increased insulin resistance
and hyperinsulinaemia which result from pharmacological
inhibition of testicular testosterone production, it is also true
that pre-existing hyperinsulinaemia, such as that seen in type
II diabetes, is associated with reduced testosterone levels.
The inverse relationship between testosterone and insulin
in males without cancer has been well documented; yet the
mechanisms linking these two hormonal pathways remain
poorly understood [24, 55, 56].
Reduced levels of free and total testosterone have been
associated with type 2 diabetes (T2DM), central adiposity,
dyslipidaemia, and hyperinsulinaemia in various studies
[24–26, 57–61], usually in combination with reduced LHRH
and LH levels however, the observation of low testosterone
levels remains relatively rare in men with type 1 diabetes
suggesting that hyperglycaemia is not a direct cause. In
addition, low androgen levels are observed in lean men with
T2DM suggesting that raised BMI is not necessary for the
persistence of hypogonadism [62]. In population studies,
following adjustment for age and adiposity, insulin was
found to be significantly and inversely correlated to free and
total testosterone levels [24]. Further, a study of middle-aged
men followed over 11 years found that low testosterone levels
were predictive for development of the metabolic syndrome
and heralded as a predictive biomarker of metabolic and
diabetic pathogenesis [58]. In contrast, high testosterone
levels are linked to insulin sensitivity, and pharmacological
improvements to insulin sensitivity increase testosterone
levels [63, 64].
Several mechanisms have been proposed which may
contribute to reduced testosterone/insulin resistance in these
cohorts. Testosterone can be converted to oestradiol through
the irreversible action of aromatase in adipose tissue. Excess
adipose tissue in obesity may increase the rate of conversion
of testosterone to oestradiol, a more potent inhibitor of
LHRH secretion from the hypothalamus. Studies investi-
gating the levels of oestradiol in these patients, however,
show mixed results. Decreased testosterone is coupled with
increased oestradiol in some studies [65, 66] while others
have shown reduced oestradiol concentrations in hypogo-
nadal men [67, 68], consistent with reduced testosterone
substrate. Differences in the sensitivity of detection methods
and duration of condition may account for discrepancies in
these reports. Hypogonadism as a result of age or in leanmen
with type 2 diabetes is likewise associated with reduced levels
of oestradiol suggesting that decreased testosterone levels in
these men is not likely to be due to oestradiol-mediated
suppression of LHRH secretion [62, 68].
LHRH and LH secretion is suppressed in animal models
by increased circulating cytokines which are elevated in
obesity [69, 70]. Related changes to the adipokine secretion
profile of men receiving ADT may also contribute to reduc-
tions in insulin sensitivity [47, 71]. Leptin and adiponectin,
circulating factors secreted by adipose tissue with known
modulatory functions on insulin sensitivity, are both ele-
vated during ADT [71, 72]. Leptin plays an important role in
appetite and energy balance, immune modulation, and bone
homeostasis [73] and is secreted from fat tissue in proportion
to adiposity. Circulating levels of leptin are increased during
ADT, in line with increased deposition of fat in these men;
however, leptin has been shown to increase even in the
absence of discernable weight gain following 28 days of ADT,
although relative fat/lean mass was not measured in this
study [71]. The profile of adiponectin secretion is generally
opposite to leptin with reduced expression and secretion
with increasing adiposity [74]. However, adiponectin is nor-
mally suppressed by testosterone [75–77], and the resulting
increase in adiponectin following ADT is attributed to the
loss of suppression by androgen. The insulin-sensitising
effects of adiponectin which may be present following ADT,
however, fail to overcome the effects of androgen withdrawal
on the development of hyperinsulinaemia [71, 72].
A recently published paper by Rubinow et al. manipu-
lated testosterone levels in young–middle-aged healthy men,
excluding patients with confounding underlying conditions
such as prostate cancer, diabetes, and hypogonadism [71].
Groups were randomised to receive ADT alone, ADT
with testosterone replacement, and ADT with testosterone
replacement and an aromatase inhibitor. Decreased insulin
sensitivity was observed in the men receiving ADT only, in
line with >90% reduction in circulating testosterone levels
which was observed in the absence of changes to body
weight and fasting glucose concentrations. Insulin sensitivity
was not affected by reduced oestradiol levels in participants
receiving the aromatase inhibitor suggesting that testosterone
is the major regulator of insulin sensitivity in healthy males.
Similar observations have been made of men receiving ADT
for prostate cancer. The rapid withdrawal of androgens with
ADT causes hyperinsulinaemia and loss of insulin sensitivity
in these patients, reflected by increased homeostatic model
assessment (HOMA) score, within 2 weeks [78] suggesting
that this is a direct effect of ADT and not subsequent to
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changes in fat mass. On the contrary, studies have shown that
insulin sensitivity following ADT is independent of fat mass
and age [48, 79].
These observations provide strong evidence for an im-
portant functional role for hyperinsulinaemia in PCa pro-
gression and CRPC following androgen deprivation. Major
findings from recent studies [54, 80] of men receiving ADT
demonstrated a strong trend between an elevated C-peptide
level and more rapid progression to CRPC. Although there
is mounting epidemiological evidence linking hyperinsuli-
naemia and CRPC, the mechanisms of insulin action directly
on PCa cells in the context of ADT has, until recently, not
been the subject of biological scrutiny.
5. Potential Mechanisms of Insulin-Androgen
Crosstalk in the Prostate
Traditionally insulin has been primarily considered a hor-
mone essential formetabolic regulation; however, insulin can
also activate lipogenesis, steroidogenesis, protein synthesis
and antiapoptotic survival pathways in many cell types [81,
82]. Insulin positively and negatively regulates approximately
150 genes; however, transcriptional factors act differently in
different target tissues; thus, insulin affects transcription by
modulation of the level, localization, and activity of tran-
scription factors differently in specific microenvironments
[82]. Insulin signals through its cognate receptor of which
there are two isoforms, INSR-A and INSR-B [81], that
belong to a family of receptor tyrosine kinases that includes
the receptor for insulin-like growth factor 1 (IGF-1R).
Many tumour types have upregulated expression of IGF-1R,
INSR, and potentially hybrid INSR/IGF-1Rs which facilitate
increased activation of mitogenic, prosurvival and protein
synthesis pathways with the increased levels of ligands insu-
lin, IGF-1, or IGF-2 [83–85]. IC50 values, calculated for each
ligand and each receptor, reveal that IGF-1 can bind the
INSR-A with ∼2.5% the efficiency of insulin and with even
weaker affinity to INSR-B. Likewise, insulin, at physiological
levels, will not activate the IGF-1R [81]. In contrast, insulin
and IGF-1 can activate signalling with varying potency
through the hybrid INSR/IGF-1R. IGF-2 is able to signal
through each of the INSR-A (weakly binds INSR-B) and
IGF-1R as well as hybrid INSR/IGF-1R. Ligand binding to
the INSR and IGF-1R activate numerous downstream path-
ways including phosphatidylinositol 3-kinase (PI3K)/Akt
and Ras/MAPK pathways with many well-characterised
downstream effects including increased glucose metabolism,
inhibition of apoptosis (e.g., via FOXO and BAD-mediated
pathways) and stimulation of cell proliferation (e.g., via
mTOR) (Figure 1) [81].
While the role of IGF-1 in cancer has been recognised for
over 20 years, the presence of the INSR directly on prostate
tumour tissue has only recently been reported and show
that increased INSR expression correlates with increasing
Gleason grade and CRPC [51] providing further evidence
that insulin and insulin receptor signallingmay have a critical
role driving progression of advanced prostate cancer. As
prostate epithelial cells are not subject to development of
insulin resistance, defined by impaired glucose uptake and
metabolism, as occurs in insulin-sensitive metabolic tissue,
hyperinsulinaemia would be expected to increase insulin
signalling in PCa cells [81] in parallel to the elevated levels
of ligand.
The molecular bases for the inverse clinical observations
between levels of insulin and testosterone are less well de-
scribed. The androgen receptor is a member of the steroid
hormone receptor family and classically controls transcrip-
tion of androgen-regulated genes in a ligand-dependent
manner; however, androgens can also elicit rapid signalling
responses independent of the AR [86, 87]. Androgen receptor
signalling plays a role in metabolic function. Direct AR-
mediated effects of testosterone on fat metabolism are
evidenced by AR knockout mice which have increased
adiposity, accompanied by elevated leptin and adiponectin
profiles and altered lipid metabolism [88], and men with
genetic androgen resistance due to defective AR expression
have increased central adiposity [89]. AR signalling inmuscle
tissue may also affect systemic insulin sensitivity. AR acti-
vation favours development of pluripotent stem cells down
the myogenic lineage via AR-dependent activity through
noncanonical Wnt signalling, favouring the formation of
muscle while suppressing the formation of new fat tissue
(adipogenesis) [90]. AR activation in muscle tissue also
increases oxidative metabolism and insulin sensitivity via
upregulation of the transcription factor PPARγ coactivator
1α (PGC1α) which stimulates mitochondrial biogenesis and
increases the oxidative potential of skeletal muscle; decreased
testosterone levels are associated with decreased PGC1α lev-
els and increased insulin resistance. The activation of PGC1α
presents a potential mechanism for cancer cell survival
that may confer increased resistance to oxidative stress and
cellular senescence by increasing oxidative phosphorylation
in the tumour cell [91, 92].
Recent reports have identified previously unappreciated
crosstalk in prostate cancer cells between the AR pathway
and PI3K signalling pathway, the major signalling pathway
activated downstream of the INSR [93–96]. The PI3K path-
way has been implicated in a number of malignancies [97]
including prostate cancer. Approximately 40% of primary
and 70% of metastatic prostate cancers have mutations
within the PI3K signalling pathway, mostly associated with
a loss of the negative regulator, PTEN [98–100]. Reciprocal
feedback regulation between androgen receptor signalling
and unfettered signalling through the PI3K-AKT-mTOR
pathway in prostate cancer [93, 95] have been shown to
inhibit AR signalling and suggest a possible pathway to
androgen-independent growth of prostate tumours [93],
and conversely, inhibition at each of these signalling nodes
was associated with enhanced AR signalling and increased
transcription of AR-responsive genes (Figure 1).
Hyperinsulinaemia and increased insulin signalling in
prostate tumour cells as a result of androgen deprivation
are likely to activate survival pathways downstream of the
insulin receptor which have the potential to contribute
to progression to castrate resistance; thus, these candidate
molecules downstream of insulin receptor signalling may
have therapeutic utility in advanced prostate cancer.
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Figure 1: Insulin receptor (INSR) belongs to a family of receptor tyrosine kinases that includes the receptor for insulin-like growth factor 1
(IGF-1R).Many tumour types have upregulated expression of IGF-1R, INSR, and potentially hybrid INSR/IGF-1Rs which facilitate increased
activation of mitogenic, prosurvival and protein synthesis pathways following activation by of ligands insulin, IGF-1 or IGF-2. IGF-1 can
bind the INSR with 2.5% the efficiency of insulin. Insulin, at physiological levels, will not activate the IGF-1R. Insulin and IGF-1 can activate
signalling with varying potency through the hybrid INSR/IGF-1R. IGF2 is able to signal through each of the INSR, IGF-1R, and hybrid
receptor (Hybrid R). Ligand binding to the INSR and IGF-1R activate numerous downstream pathways including phosphatidylinositol
3 kinase (PI3K)/Akt and Ras/MAPK pathways with many well-characterised downstream effects including increased glucose metabolism,
inhibition of apoptosis (e.g., via FOXO and BAD-mediated pathways), and stimulation of cell proliferation (e.g., via mammalian target of
rapamycin; mTOR). Reciprocal feedback regulation occurs in prostate cancer cells between the AR signalling and signalling through the
PI3K-AKT-mTOR pathway. Unfettered activity through this pathway, associated with the common PTEN mutation, inhibits AR signalling
and suggests a possible pathway to androgen-independent growth of prostate tumours. AMP-activated protein kinase (AMPK) is a potentially
bifunctional modulator in prostate cancer cells. Activation of AMPK modulates insulin signalling by negatively regulating mTOR control
of protein synthesis and halting cell proliferation. AMPK activation also promotes fatty acid oxidation and downregulates expression of
SREBP and activity of acetyl-CoA carboxylase (ACC) resulting in decreased fatty acid synthesis. However, AMPK has complex regulation in
prostate cancer cells andmay potentiate increased proliferation andmigration when activated downstream of the AR under the control of AR
responsive regulator calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2). AR directly regulates CAMKK2 and upregulates
AMPK which mediates AR-induced migration and invasion in a CAMKK2-dependent manner. In studies where metformin activation of
AMPK results in cessation of cancer cell growth, signalling is thought to be through LKB-1 tumour suppressor; therefore, competition
for AMPK signalling via LKB1 stimulation versus AR-mediated CAMKK2 activation could result in altered functional outcomes. DHT,
dihydrogen testosterone; AR, androgen receptor; ARE, androgen response element; MAPK, mitogen-activated protein kinase.
6. Diabetes, Prostate Cancer, and Metformin
Diabetes has been shown to be associated with increased
risk of several cancers including colon, pancreatic, and
breast cancer [101]. In contrast studies have found that
diabetics have lower PCa risk than nondiabetics [102, 103],
perhaps related to decreased levels of androgens [103–
105]. Metformin, which works in part by activating AMP-
activated protein kinase (AMPK), is used clinically in obese
and diabetic patients to normalise circulating insulin levels
primarily via reduced hepatic glucose output, and promising
data emerging from clinical studies suggests that metformin
may improve patient outcomes in prostate and other cancers
[106–110]. A retrospective cohort study compared diabetic
patients on metformin against matched diabetic patients not
receiving metformin and showed a significantly decreased
risk of cancer diagnosis of the metformin group with an
adjusted hazard ratio of 0.63 (95% CI 0.53–0.75) and
decreased cancer-related mortality, as well as a prolonged
median time to cancer diagnosis [111]. These results were
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supported by an observational study of 11,876 diabetic
patients demonstrating a 33% decreased risk of develop-
ing cancer with metformin treatment compared to other
treatments [112]. In contrast, metformin gave no benefit
to prostate cancer risk compared to controls in a recent
report; on the contrary, metformin treatment was reported
to increase the risk of prostate cancer diagnosis back up
to normal levels [113] possibly due to the normalisation of
androgen levels associated with stabilisation of insulin levels.
Based on these results, targeting AMP-activated protein
kinase (AMPK) has been proposed as a therapeutic strategy
in cancer [114, 115]. Reports indicate that pharmacological
activation of AMPK in cancer cells by either metformin
or AICAR results in halting cell proliferation by negatively
regulating mammalian target of rapamycin (mTOR) control
of protein synthesis (Figure 1) [101, 116–118]. In vitro
studies of metformin also demonstrate an antitumoral effect
in prostate cancer cells by blocking cell cycle progression
and decreasing cyclin D1 protein levels resulting in reduced
LNCaP xenograft tumour growth [107]. AMPK activation
also promotes fatty acid oxidation reducing availability of
fatty acids for biosynthetic pathways and downregulating
expression of SREBP and phosphorylation/deactivation of
acetyl-CoA carboxylase (ACC) resulting in decreased fatty
acid synthesis (Figure 1) [119].
Activation of AMPK modulates insulin signalling down-
stream of the insulin receptor [120], most notably via
differentially phosphorylating the tuberous sclerosis complex
TSC1-TSC2 to inactivate mTOR [118, 121]. The ability of
AMPK to potentiate insulin action on cancer cell growth
and survival has not been greatly explored in models of
prostate cancer. Indeed the effects of metformin have not
yet been demonstrated to be direct effects on cancer cells
or an indirect consequence of systemic insulin normalisation
[115]. Nevertheless, the intersection between mTOR, insulin
signaling, and AMPK provides an intriguing, tantalising link
between cellular energy and cancer pathways.
Recent data suggests that AMPK activation may have
more complex regulation in prostate cancer cells and may
potentiate increased prostate cancer cell proliferation and
migration when activated downstream of the androgen
receptor (AR) [122, 123]. Using elegant integrated bioin-
formatic analyses of transcriptional profiling with AR ChIP
analysis, Massie et al. recently identified AR-mediated upreg-
ulation of several metabolic pathways including increased
aerobic glycolysis under the control of a master regula-
tor calcium/calmodulin-dependent protein kinase kinase 2
(CAMKK2) [123]. AR directly regulates CAMKK2 by bind-
ing to its promoter and is highly expressed in normal
prostate with elevated expression in both AR-sensitive and
CRPC models of prostate cancer [122, 123]. Intriguingly,
AR activation was also shown to upregulate the primary
CAMKK2 substrate AMPK [122–124] which mediated AR-
induced migration and invasion in a CAMKK2-dependent
manner (Figure 1). Massie et al. found that CAMKK2 activa-
tion of AMPK promoted glycolysis but negatively regulated
biosynthesis though mTOR pathways consistent with pre-
vious reports of AMPK inhibitory effect on components of
the mTOR pathway [117, 118]. Similarly, in an earlier report,
activation of AMPK was sufficient to increase cell migration
via potentiation of Rac1 activity, a regulator of cell migration
[122, 125]. Alternative cofactors yet to be identified may
regulate this effect of AMPK, specifically downstream of AR
signalling.
In studies where metformin activation of AMPK results
in cessation of cancer cell growth, signalling is thought be
through LKB-1 tumour suppressor [126]; therefore, the dif-
ference in these functional outcomes of AMPK activa-
tion could be the company it keeps. Competition for
AMPK signalling via LKB1 stimulation versus AR-mediated
CAMKK2 activation could result in decreased mTOR sig-
nalling and decreased glucose (fuel) for anabolic pathways.
Taken together, it seems that AMPK at the cellular level is
a potentially bi-functional modulator. This latter role for
AMPK is in contrast to earlier reports which show that
metformin reduced cancer cell proliferation [107, 117, 127,
128] via inhibition of anabolic pathways such as lipogenesis
[119, 129] starving the major bioenergetic pathway in
prostate cancer cells [130]. Nevertheless, we should interpret
with caution the effect of metformin from men with pre-
existing obesity or type 2 diabetes where, in contrast to
other cancers, diabetes appears to protect from cancer, while
metformin may increase the risk of diagnosis or more likely
mitigate the PCa risk-reducing benefit of diabetes in these
patients. Several clinical trials are currently addressing the
benefit of metformin treatment in men on ADT without
pre-existing diabetes. The outcomes of these trials will be of
significant clinical interest.
7. Targeting the Insulin Axis in Advanced
Prostate Cancer
Reactivation of the AR following ADT, heralded by rising
serum PSA, is a hallmark of CRPC progression. We and
others have demonstrated in recent years that intratumoral
androgen synthesis is a major contributor to reactivation
of AR in CRPC [39, 40, 131, 132]. Moreover, we have
noted that insulin promotes steroidogenesis in other cell
types [133–135]. From these merging hypotheses, we have
recently reported that insulin, in the absence of androgen,
may drive PCa progression in part through upregulation of
SREBP and its downstream enzymes responsible for lipid and
steroid synthesis in cell models of prostate cancer, resulting
in dramatically increased intratumoral steroid production
which is sufficient to reactivate the AR to stimulate PSA
expression and secretion [136]. Thus, insulin can act directly
on PCa cells to activate pathways contributing to CRPC
progression.
In addition to activation of de novo steroid synthesis,
insulin is capable of driving numerous transcriptional pro-
grams predominantly downstream of PI3K/AKT signalling.
Pathways activated in response to cell stress (e.g., glucose
starvation, hypoxia) are associated with increased cancer
cell survival, via both pro-proliferative and antiapoptotic
mechanisms and underpin treatment resistance [137–140].
Many of these pathways are modulated by highly con-
served signalling molecules including insulin, target of
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rapamycin (mTOR) and AMP-activated protein kinase
(AMPK), each of which maintain cellular homeostasis by
sensing/signalling nutrient, energy, and oxygen availability.
These molecules integrate cellular energy and metabolism
with stress response pathways leading to cancer cell survival.
More recently, the insulin-sensitising class of drugs, thiazo-
lidinediones, has also been associated with improved survival
of diabetic prostate cancer patients [63] revealing several
potential nodes of therapeutic intervention which warrant
further research.
8. Conclusions
Prostate cancer is the most common cancer in men [30],
increases sharply after age 50, and will continue to rise with
our ageing population. At the same time, we face the growing
epidemic of obesity and associated metabolic syndrome
while the risk of aggressive prostate cancer is increased 3-fold
with obesity. Therapy for local control will fail in 25–40%
of prostate cancer patients, and these men will subsequently
be treated with ADT [32]. While initially improving cancer
control, ADT induces hyperinsulinaemia [32, 34–36]. We
have shown that insulin acts directly on prostate tumour cells
to increase intratumoural androgen production. However,
it is likely that additional highly relevant cancer pathways
are activated by high insulin levels that promote metastases,
tumour growth, and treatment resistance and that the
crosstalk between these pathways and AR signalling may
be highly relevant to the progression to castrate-resistant
disease, possibly independently of AR signalling.
Standard chemotherapeutic agents have limited benefit
in CRPC and while next-generation anti-androgen therapies
are improving, they still result in resistance, highlighting the
urgent need to understand mechanisms underlying treat-
ment resistance and find rationally informed treatment
options. Currently, ADT-induced hyperinsulinaemia is not
addressed in prostate cancer patients, despite a significantly
increased risk of cardiovascular and cancer-related mortality
in these patients [141]; however, a review of the literature
suggests that management of the hyperinsulinaemia induced
by ADT may be a useful adjunct to current standard prostate
cancer treatments.
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